Several studies have found a strong correlation between unfavorable prognosis of COVID‐19 with high levels of inflammatory cytokines,[27] especially with IL‐6 and CRP.[28, 29, 30, 31, 32] Furthermore, taking into consideration the short half‐life of cytokines, and that some diseases display an acute onset (as with COVID‐19), development of fast, accurate, and reliable cytokine biosensors has emerged as an imperative need for point‐of‐care (PoC) testing.[33]. The gene discussed is IL6; the disease is COVID-19.